A Randomized, Placebo-Controlled Trial to Assess the Effects of 8 Weeks of Administration of GSK256073, a Selective GPR109A Agonist, on High-Density Lipoprotein Cholesterol in Subjects With Dyslipidemia.
Clin Pharmacol Drug Dev
; 8(7): 871-883, 2019 10.
Article
in En
| MEDLINE
| ID: mdl-31268250
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Xanthines
/
Dyslipidemias
/
Flushing
/
Cholesterol, HDL
Type of study:
Clinical_trials
Limits:
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Language:
En
Journal:
Clin Pharmacol Drug Dev
Year:
2019
Document type:
Article